WJCD  Vol.2 No.4 , October 2012
Levosimendan usage in patients with left ventricle dysfunction in coronary artery bypass graft surgery
ABSTRACT
Introduction: In this study we explicated early results of patients (the patients in whom levosimendan was used) who underwent coronary artery bypass graft surgery with ejection fraction 35% or less. We compared this group with the patients in whom levo-simendan was not used. Material and Methods: 97 patients who have 35% ejection fraction or less taken to isolated coronary artery bypass surgery between January 2009 and December 2011 in our clinic are chosen for this study retrospectively. We compared the patients in whom levosimendan was used with the patients in whom levosimendan was not used. Levo- simendan (Simdax, Abbott) has been used according to surgeon’s decision in patients. Results: The mean age of group 1 was 62.3 ± 7.6, and the mean age of group 2 was 59.3 ± 10.5 (p > 0.05). It was detected that the average ejection fraction was less in group 1 (p < 0.05). There were no statistically significant difference between the two groups in terms of demand for inotropics, demand for intraaortic balloon pump, revision (because of bleeding), atrial fibrillation, discharging intervals, intensive care unit time, cross clamp and cardiopulmonary bypass time (p > 0.05). It was found that need for blood transfusion were less in group 1 than group 2 (p < 0.05). There were no statistically significant difference between the two groups in terms of mortality (p > 0.05). Conclusion: We consider levosimendan reduces need for blood transfusion in coronary artery bypass graft surgery. This results may change with increasing number of patients so we consider that multicenter larger study is needed.

Cite this paper
Cakir, H. , Tor, F. , Uncu, H. , Gur, O. , Acipayam, M. and Ibrahim, O. (2012) Levosimendan usage in patients with left ventricle dysfunction in coronary artery bypass graft surgery. World Journal of Cardiovascular Diseases, 2, 291-294. doi: 10.4236/wjcd.2012.24045.
References
[1]   Suzer, O., Bozkurt, A.K., Suzer, A., Aykac, Z. and Barlas, A. (1996) The comparison of the ?notropic effects of levosimendan and amrinone after ischemia in ?solated perfused guinea pig hearts. Turk Gogus Kalp Dama, 1, 5-8.

[2]   Tritapepe, L., De Santis, V., Vitale, D., Guarracino, F., Pellegrini, F., Pietropaoli, P., et al. (2009) Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia, 102, 198-204. doi:10.1093/bja/aen367

[3]   Maltais, S., Ladouceur, M. and Cartier, R. (2011) The influence of a low ejection fraction on long-term survival in systematic off-pump coronary artery bypass surgery. British Journal of Anaesthesia, 39, 122-127. doi:10.1016/j.ejcts.2010.12.022

[4]   Lahtinen, P., Pitk?nen, O., P?l?nen, P., Turpeinen, A., Kiviniemi, V. and Uusaro, A. (2011) Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial. Critical Care Medicine, 39, 2263-2270. doi:10.1097/CCM.0b013e3182227b97

[5]   Malliotakis, P., Xenikakis, T., Linardakis, M. and Hassoulas, J. (2007) Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: A case series. The Hellenic Journal of Cardiology, 48, 80-88.

[6]   Tasouli, A., Papadopoulos, K., Antoniou, T., Kriaras, I., Stavridis, G., Degiannis, D., et al. (2007) Efficacy and safety of perioperative infusion of levosimendan in pa- tients with compromised cardiac function undergoing open-heart surgery: Importance of early use. European Journal Cardio—Thoracic Surgery, 32, 629-633. doi:10.1016/j.ejcts.2007.07.010

[7]   Kolseth, S.M., Nordhaug, D.O., Stenseth, R., Sellevold, O., Kirkeby-Garstad, I. and Wahba, A. (2009) Prophy- lactic treatment with levosimendan: A retrospective matched- control study of patients with reduced left ventricular function. European Journal Cardio—Thoracic Surgery, 36, 1024-1030. doi:10.1016/j.ejcts.2009.05.001

[8]   Maisel, W.H., Rawn, J.D. and Stevenson, W.G. (2001) Atrial fibrillation after cardiac surgery. Annals of Internal Medicine, 18, 1061-1073.

[9]   Tek, M., Cavusoglu, Y., Demirustu, C., Birdane, A., Unalir, A., Gorenek, B., et al. (2010) Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure. Archives of the Turkish Society of Cardiology, 38, 334-340.

[10]   Maharaj, R. and Metaxa, V. (2011) Levosimendan and mortality after coronary revascularisation: A meta-analysis of randomised controlled trials. Critical Care, 15, R140. doi:10.1186/cc10263

 
 
Top